Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Nature Communications|November 22, 2019
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impactLisanne F van Dessel, Job van Riet, Minke Smits, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2021
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cellsLisanne Mout, Lisanne F van Dessel, Jaco Kraan, et al.
Cancer|November 16, 2019
Platinum exposure and cause-specific mortality among patients with testicular cancerHarmke J Groot, Flora E van Leeuwen, Sjoukje Lubberts, et al.
Nature Communications|February 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerMaud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Nature Communications|November 22, 2019
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impactLisanne F van Dessel, Job van Riet, Minke Smits, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 2021
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cellsLisanne Mout, Lisanne F van Dessel, Jaco Kraan, et al.
Cancer|November 16, 2019
Platinum exposure and cause-specific mortality among patients with testicular cancerHarmke J Groot, Flora E van Leeuwen, Sjoukje Lubberts, et al.
Nature Communications|February 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerMaud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Pageof 18